Literature DB >> 23525330

State-dependent etomidate occupancy of its allosteric agonist sites measured in a cysteine-substituted GABAA receptor.

Deirdre S Stewart1, Mayo Hotta, Rooma Desai, Stuart A Forman.   

Abstract

A central axiom of ligand-receptor theory is that agonists bind more tightly to active than to inactive receptors. However, measuring agonist affinity in inactive receptors is confounded by concomitant activation. We identified a cysteine substituted mutant γ-aminobutyric acid type A (GABAA) receptor with unique characteristics allowing the determination of allosteric agonist site occupancy in both inactive and active receptors. Etomidate, the allosteric agonist, is an anesthetic that activates or modulates α1β2γ2L GABAA receptors via transmembrane sites near β2M286 residues in M3 domains. Voltage-clamp electrophysiology studies of α1β2M286Cγ2L receptors show that GABA is an efficacious agonist and that etomidate modulates GABA-activated activity, but direct etomidate agonism is absent. Quantitative analysis of mutant activity using an established Monod-Wyman-Changeux (MWC) allosteric model indicates that the intrinsic efficacy of etomidate, defined as its relative affinity for active versus inactive receptors, is lower than in wild-type receptors. Para-chloromercuribenzene sulfonate covalently modifies β2M286C side-chain sulfhydryls, irreversibly altering GABA-induced currents. Etomidate concentration dependently reduces the apparent rate of β2M286C-pCMBS bond formation, tracked electrophysiologically. High etomidate concentrations completely protect the β2M286C suflhydryl from covalent modification, suggesting close steric interactions. The 50% protective etomidate concentration (PC50) is 14 μM in inactive receptors and 1.1 to 2.2 μM during GABA-activation, experimentally demonstrating that activated receptors bind etomidate more avidly than do inactive receptors. The experimental PC50 values are remarkably close to, and therefore validate, MWC model predictions for etomidate dissociation constants in both inactive and active receptors. Our results support MWC models as valid frameworks for understanding the agonism, coagonism, and modulation of ligand-gated ion channels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23525330      PMCID: PMC3657098          DOI: 10.1124/mol.112.084558

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  24 in total

Review 1.  Allostery and the Monod-Wyman-Changeux model after 50 years.

Authors:  Jean-Pierre Changeux
Journal:  Annu Rev Biophys       Date:  2012-01-06       Impact factor: 12.981

2.  Two etomidate sites in α1β2γ2 γ-aminobutyric acid type A receptors contribute equally and noncooperatively to modulation of channel gating.

Authors:  Grigori Guitchounts; Deirdre S Stewart; Stuart A Forman
Journal:  Anesthesiology       Date:  2012-06       Impact factor: 7.892

3.  Thinking in cycles: MWC is a good model for acetylcholine receptor-channels.

Authors:  Anthony Auerbach
Journal:  J Physiol       Date:  2011-08-01       Impact factor: 5.182

4.  Structure and dynamics of the GABA binding pocket: A narrowing cleft that constricts during activation.

Authors:  D A Wagner; C Czajkowski
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

5.  Gating-induced conformational rearrangement of the γ-aminobutyric acid type A receptor β-α subunit interface in the membrane-spanning domain.

Authors:  Moez Bali; Myles H Akabas
Journal:  J Biol Chem       Date:  2012-06-22       Impact factor: 5.157

6.  Mapping general anesthetic binding site(s) in human α1β3 γ-aminobutyric acid type A receptors with [³H]TDBzl-etomidate, a photoreactive etomidate analogue.

Authors:  David C Chiara; Zuzana Dostalova; Selwyn S Jayakar; Xiaojuan Zhou; Keith W Miller; Jonathan B Cohen
Journal:  Biochemistry       Date:  2012-01-23       Impact factor: 3.162

7.  Methionine 286 in transmembrane domain 3 of the GABAA receptor beta subunit controls a binding cavity for propofol and other alkylphenol general anesthetics.

Authors:  M D Krasowski; K Nishikawa; N Nikolaeva; A Lin; N L Harrison
Journal:  Neuropharmacology       Date:  2001-12       Impact factor: 5.250

8.  An allosteric coagonist model for propofol effects on α1β2γ2L γ-aminobutyric acid type A receptors.

Authors:  Dirk Ruesch; Elena Neumann; Hinnerk Wulf; Stuart A Forman
Journal:  Anesthesiology       Date:  2012-01       Impact factor: 7.892

9.  Numerous classes of general anesthetics inhibit etomidate binding to gamma-aminobutyric acid type A (GABAA) receptors.

Authors:  Guo-Dong Li; David C Chiara; Jonathan B Cohen; Richard W Olsen
Journal:  J Biol Chem       Date:  2010-01-18       Impact factor: 5.157

10.  Gamma-amino butyric acid type A receptor mutations at beta2N265 alter etomidate efficacy while preserving basal and agonist-dependent activity.

Authors:  Rooma Desai; Dirk Ruesch; Stuart A Forman
Journal:  Anesthesiology       Date:  2009-10       Impact factor: 7.892

View more
  17 in total

1.  A Cysteine Substitution Probes β3H267 Interactions with Propofol and Other Potent Anesthetics in α1β3γ2L γ-Aminobutyric Acid Type A Receptors.

Authors:  Alex T Stern; Stuart A Forman
Journal:  Anesthesiology       Date:  2016-01       Impact factor: 7.892

Review 2.  Mapping General Anesthetic Sites in Heteromeric γ-Aminobutyric Acid Type A Receptors Reveals a Potential For Targeting Receptor Subtypes.

Authors:  Stuart A Forman; Keith W Miller
Journal:  Anesth Analg       Date:  2016-11       Impact factor: 5.108

Review 3.  Comparison of αβδ and αβγ GABAA receptors: Allosteric modulation and identification of subunit arrangement by site-selective general anesthetics.

Authors:  Hua-Jun Feng; Stuart A Forman
Journal:  Pharmacol Res       Date:  2017-12-30       Impact factor: 7.658

4.  Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors.

Authors:  Manoj Kumar; Lorie A González; Glenn H Dillon
Journal:  Neuropharmacology       Date:  2015-04-18       Impact factor: 5.250

5.  Cysteine substitutions define etomidate binding and gating linkages in the α-M1 domain of γ-aminobutyric acid type A (GABAA) receptors.

Authors:  Deirdre S Stewart; Mayo Hotta; Guo-Dong Li; Rooma Desai; David C Chiara; Richard W Olsen; Stuart A Forman
Journal:  J Biol Chem       Date:  2013-09-05       Impact factor: 5.157

6.  Etomidate and Etomidate Analog Binding and Positive Modulation of γ-Aminobutyric Acid Type A Receptors: Evidence for a State-dependent Cutoff Effect.

Authors:  Megan McGrath; Zhiyi Yu; Selwyn S Jayakar; Celena Ma; Mansi Tolia; Xiaojuan Zhou; Keith W Miller; Jonathan B Cohen; Douglas E Raines
Journal:  Anesthesiology       Date:  2018-11       Impact factor: 7.892

7.  Alphaxalone Binds in Inner Transmembrane β+-α- Interfaces of α1β3γ2 γ-Aminobutyric Acid Type A Receptors.

Authors:  Alexis M Ziemba; Andrea Szabo; David W Pierce; Marian Haburcak; Alex T Stern; Anahita Nourmahnad; Elizabeth S Halpin; Stuart A Forman
Journal:  Anesthesiology       Date:  2018-02       Impact factor: 7.892

8.  Tryptophan and Cysteine Mutations in M1 Helices of α1β3γ2L γ-Aminobutyric Acid Type A Receptors Indicate Distinct Intersubunit Sites for Four Intravenous Anesthetics and One Orphan Site.

Authors:  Anahita Nourmahnad; Alex T Stern; Mayo Hotta; Deirdre S Stewart; Alexis M Ziemba; Andrea Szabo; Stuart A Forman
Journal:  Anesthesiology       Date:  2016-12       Impact factor: 7.892

9.  Etomidate produces similar allosteric modulation in α1β3δ and α1β3γ2L GABA(A) receptors.

Authors:  H-J Feng; Y Jounaidi; M Haburcak; X Yang; S A Forman
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

10.  Assessment of homology templates and an anesthetic binding site within the γ-aminobutyric acid receptor.

Authors:  Edward J Bertaccini; Ozge Yoluk; Erik R Lindahl; James R Trudell
Journal:  Anesthesiology       Date:  2013-11       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.